Phase I Clinical Trial Combining Imatinib Mesylate and IL-2

OncoImmunology - United States
doi 10.4161/onci.23080
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Imatinib Mesylate for Plexiform Neurofibromas in Patients With Neurofibromatosis Type 1: A Phase 2 Trial

The Lancet Oncology
Oncology
2012English

A Dose-Escalating Phase I of Imatinib Mesylate With Fixed Dose of Metronomic Cyclophosphamide in Targeted Olid Tumours

British Journal of Cancer
Cancer ResearchOncology
2013English

Phase I/Ii Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers

Oncologist
Cancer ResearchMedicineOncology
2015English

Imatinib and Everolimus in Patients With Progressing Advanced Chordoma: A Phase 2 Clinical Study

Cancer
Cancer ResearchOncology
2018English

Phase I Clinical Trial of Temsirolimus and Perifosine for Recurrent Glioblastoma

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2020English

Imatinib Mesylate Causes Growth Plate Closure in Vivo

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Imatinib Mesylate Inhibits Fibrogenesis in Asbestos-Induced Interstitial Pneumonia

Experimental Lung Research
Respiratory MedicinePulmonaryClinical BiochemistryMolecular Biology
2007English

Reduced-Intensity Allogeneic Transplantation Combined With Imatinib Mesylate for Chronic Myeloid Leukemia in First Chronic Phase

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Evaluation of Wearable Digital Devices in a Phase I Clinical Trial

Clinical and Translational Science
GeneticsMolecular BiologyPharmacologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy